CA2643633A1 - Utilisation d'un anticorps dirige contre un peptide de beta-amyloide pour le traitement de la maladie d'alzheimer - Google Patents

Utilisation d'un anticorps dirige contre un peptide de beta-amyloide pour le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
CA2643633A1
CA2643633A1 CA002643633A CA2643633A CA2643633A1 CA 2643633 A1 CA2643633 A1 CA 2643633A1 CA 002643633 A CA002643633 A CA 002643633A CA 2643633 A CA2643633 A CA 2643633A CA 2643633 A1 CA2643633 A1 CA 2643633A1
Authority
CA
Canada
Prior art keywords
antibody
administered
dosage
ser
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002643633A
Other languages
English (en)
Inventor
Ivan Lieberburg
Jim Callaway
Michael Grundman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland UC
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2007/009499 external-priority patent/WO2009017467A1/fr
Publication of CA2643633A1 publication Critical patent/CA2643633A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des gammes de dosage, des concentrations maximales, des concentrations moyennes et des régimes de surveillance préférés pour une utilisation dans le traitement de la maladie d'Alzheimer à l'aide d'anticorps dirigés contre A-bêta. L'invention porte également sur les régimes de surveillance qui peuvent évaluer des changements de symptômes ou de signes d'un patient suivant un traitement.
CA002643633A 2006-04-18 2007-04-18 Utilisation d'un anticorps dirige contre un peptide de beta-amyloide pour le traitement de la maladie d'alzheimer Abandoned CA2643633A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79301406P 2006-04-18 2006-04-18
US60/793,014 2006-04-18
PCT/US2007/009499 WO2009017467A1 (fr) 2007-07-27 2007-07-27 Traitement de maladies amyloïdogéniques

Publications (1)

Publication Number Publication Date
CA2643633A1 true CA2643633A1 (fr) 2007-10-18

Family

ID=40451045

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002643633A Abandoned CA2643633A1 (fr) 2006-04-18 2007-04-18 Utilisation d'un anticorps dirige contre un peptide de beta-amyloide pour le traitement de la maladie d'alzheimer

Country Status (1)

Country Link
CA (1) CA2643633A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101481421B (zh) * 2009-02-04 2012-06-27 吉林大学 一种用于治疗老年痴呆症的重组抗原多肽及多肽基因

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101481421B (zh) * 2009-02-04 2012-06-27 吉林大学 一种用于治疗老年痴呆症的重组抗原多肽及多肽基因

Similar Documents

Publication Publication Date Title
US8613920B2 (en) Treatment of amyloidogenic diseases
US8784810B2 (en) Treatment of amyloidogenic diseases
CA2590337C (fr) Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
WO2010044803A1 (fr) Traitement de maladies amyloïdogènes
EP1838854B1 (fr) Anticorps reconnaissant le peptide beta amyloide
AU2006211184B8 (en) Anti a beta antibody formulation
US8128928B2 (en) Humanized antibodies that recognize beta amyloid peptide
EP2207565B1 (fr) Régimes immunothérapeutiques dépendant du statut de l'apoe
EP2205631B1 (fr) Anticorps humanisé
US20060257396A1 (en) Abeta antibodies for use in improving cognition
JP2022058369A (ja) アルツハイマー病治療方法
CA2643633A1 (fr) Utilisation d'un anticorps dirige contre un peptide de beta-amyloide pour le traitement de la maladie d'alzheimer
JP2014001232A (ja) アミロイド原性疾患の処置
JP2016047839A (ja) アミロイド原性疾患の処置
JP2012050437A (ja) ベータアミロイドペプチドを認識するヒト化抗体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20180515